FY2025 · ended Dec 31, 2025 · Revenue $622,489, -84.1% YoY · Filed Mar 31, 2026
Co-Diagnostics, Inc. (CODX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $622,489 and a net loss of $46.9 million. Free cash flow was -$29.8 million. As of Jun 30, 2026 it held $3.6 million in cash and investments and $1.8 million in total debt.
Revenue (TTM)
$721,386
-28.1% vs year-ago TTM
Net income (TTM)
$-47.06M
-30.7% vs year-ago TTM
Operating cash flow (TTM)
$-27.10M
+16.6% vs year-ago TTM
Free cash flow (TTM)
$-27.47M
+17.3% vs year-ago TTM
EPS (TTM)
$-19.45
-822.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
3.60M
-89.3% vs prior year
Net cash
$1.85M
as of Jun 30, 2026
Operating margin
-6787.6%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CODX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1692415
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $622,489 | $3.9M | $6.8M | $34.2M | $97.9M |
| Operating income | -$50.2M | -$40.1M | -$42.7M | -$27.0M | $46.1M |
| Net income | -$46.9M | -$37.6M | -$35.3M | -$14.2M | $36.7M |
| Diluted EPS | -$35.25 | -$37.22 | -$1.20 | -$0.45 | $1.23 |
| Operating cash flow | -$29.1M | -$29.2M | -$22.1M | $6.6M | $41.1M |
| Free cash flow | -$29.8M | -$29.9M | -$23.4M | $5.1M | $40.4M |
| Total assets | $24.7M | $63.6M | $95.3M | $123.1M | $160.0M |
| Total liabilities | $4.1M | $9.7M | $9.3M | $8.6M | $25.6M |
| Stockholders' equity | $20.6M | $53.9M | $85.6M | $114.5M | $134.5M |
| Cash and investments | $11.9M | $29.7M | $58.5M | $81.3M | $89.9M |
| Total debt | $1.2M | $2.2M | $3.0M | $347,917 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K/A |
Amended current report
Material agreement, New debt, Unregistered share sale
|
Oct 15, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 13, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 25, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
All 390 Co-Diagnostics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.